What are the potential side effects of taking meltjaro?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Was this fact-check helpful?
1. Summary of the results
The potential side effects of taking Meltjaro (tirzepatide) include gastrointestinal adverse events such as nausea, diarrhea, vomiting, constipation, decreased appetite, dyspepsia, and abdominal pain, which are generally mild-to-moderate and dose-related [1] [2] [3]. Serious adverse events reported include severe GI problems, acute kidney injury, gallbladder disease, pancreatitis, hypoglycaemia when combined with other diabetes drugs, and a risk of thyroid (medullary) cancer [4] [2]. Injection-site reactions, nasopharyngitis, and metabolic disturbances such as increased blood glucose are also reported [5] [6]. The need for monitoring pancreatic and renal function while on the drug is emphasized [7]. Real-world safety concerns include frequent dosing errors, injection-site reactions, GI complaints, off-label use, and metabolic disturbances [6].
2. Missing context/alternative viewpoints
- The analyses highlight the importance of dose-related side effects, with higher doses associated with a greater risk of gastrointestinal adverse events [1].
- Alternative viewpoints on the safety profile of Meltjaro are presented, with some sources reporting a lower risk of serious adverse events [3] and others highlighting real-world safety concerns [6].
- Missing context includes the long-term effects of taking Meltjaro, with possible persistent digestive issues, kidney or gallbladder problems, and the need for monitoring [4].
- Different populations may be affected differently by Meltjaro, with caution in pregnancy and contraindication in severe GI disease noted [2].
- Combination with other medications may increase the risk of hypoglycaemia and other adverse events [4] [2].
3. Potential misinformation/bias in the original statement
The original statement asks about the potential side effects of taking Meltjaro, but does not provide context on the dose-related nature of these side effects [1]. Pharmaceutical companies may benefit from downplaying the risk of serious adverse events, while patient advocacy groups may emphasize the need for monitoring and caution [7] [6]. Healthcare providers may benefit from highlighting the importance of proper dosing and patient education to minimize the risk of adverse events [6]. Researchers may have a vested interest in presenting a balanced view of the safety profile of Meltjaro, including both common and serious adverse events [1] [3].